Return |
Four high-quality observational studies were included. In pregnant patients who were not started on anticoagulants because their D-dimer test was negative, 1 patient out of 312 had a DVT or PE after 3-months of follow-up.
Understanding the problem
The risk of VTE is increased 10 to 20 times in pregnancy compared to the general population. This is in part due to some changes in hormone levels and to compression of veins in the legs by the enlarging uterus. Doctors worry about VTE during pregnancy, as it is a leading cause of maternal death in Western countries.
VTE can be difficult to identify during pregnancy because some signs overlap with changes that occur in a regular pregnancy (e.g., shortness of breath, lower extremity swelling). In patients who have symptoms but are not pregnant, doctors use a checklist of questions (score) to decide if the patient is likely or unlikely to have DVT or PE. A D-dimer blood test is often combined with the score from the checklist to decide who needs imaging and who does not. In pregnancy, these tools are not typically used because they have not been well studied.
VTE is usually ruled out with imaging (ultrasound of the legs or CT scan of the chest) during pregnancy. The amount of radiation due to a CT scan of the chest during pregnancy is well below the accepted level for safety for both mom and baby. Nevertheless, concerns about radiation exposure can cause anxiety in pregnant patients. Recently, studies have looked at the role of the D-dimer in ruling out VTE in pregnant patients. The reviewers wanted to know if using a D-dimer blood test can safely rule out VTE in pregnant patients without the need for imaging.
A summary of four observational studies published up to June 2021.
Who? The studies included between 149 and 498 pregnant patients who had signs and/or symptoms of an acute DVT or PE. A total of 836 patients were included in the analysis.
What? The studies evaluated the use of D-dimer levels in the blood to rule out VTE.
Rate of VTE in patients with a negative D-dimer
Study | VTE rate at 3 months in the negative D-dimer group |
---|---|
Righini and colleagues | 0 out of 46 patients |
Van der Pol and colleagues | 1 out of 164 patients |
Chan and colleagues | 0 out of 69 patients |
Choi and colleagues | 0 out of 33 patients |
Overall 3-month VTE rate | About 1 patient out of 300 who had a negative D-dimer had VTE |
This Evidence Summary is based on the following article:
Bellesini M, Robert-Ebadi H, Combescure C, et al. D-dimer to rule out venous thromboembolism during pregnancy: A systematic review and meta-analysis. J Thromb Haemost. 2021 Oct;19(10):2454-2467. doi: 10.1111/jth.15432. Epub 2021 Jul 20. PubMed
Dr. Camille Simard
Dr. Camille Simard is a general internist who graduated from McGill University and is currently completing an Obstetric Medicine fellowship at Centre Hospitalier Universitaire (CHU) Sainte-Justine in Montreal. She is also completing a master’s degree in Epidemiology and Biostatistics via the Clinician Investigator Program at McGill University. Starting in July 2022, Dr. Simard will be starting a clinical fellowship in Thrombosis Medicine at the University of Ottawa. Dr. Simard has clinical expertise in obstetric medicine, and a research focus on venous thromboembolism (VTE) and bleeding complications related to anticoagulant use in pregnancy.
Lori-Ann Linkins, MD, MSc (Clin Epi), FRCPC
Dr. Linkins is an Associate Professor of Medicine (thrombosis) at McMaster University in Hamilton, Canada. She holds a Masters Degree in Health Research Methodology and is a Deputy Editor with the Health Information Research Unit, McMaster. She is Co-Editor of the ACP Journal Club and Co-lead on the CanVECTOR Knowledge Translation Platform.
Published: Wednesday, June 22, 2022
Please note that the information contained herein is not to be interpreted as an alternative to medical advice from a professional healthcare provider. If you have any questions about any medical matter, you should consult your professional healthcare providers, and should never delay seeking medical advice, disregard medical advice or discontinue medication based on information provided here.
This Evidence Summary was printed from the CLOT+ website on 2025/03/30. To view other Evidence Summaries or to register to receive email notifications about new Evidence Summaries, please visit us at https://plus.mcmaster.ca/ClotPlus/Articles/EvidenceSummaries |
![]() |